Pancreatic Diseases Clinical Trial
Official title:
Safety and Efficacy of the New 20 mm Lumen Apposing Metal Stent (Lams) for Endoscopic Treatment of Pancreatic and Peripancreatic Fluid Collections: a Large, International, Multicenter Study
Pancreatic fluid collections (PFC) can occur as a complication of acute and chronic
pancreatitis. PFC include pancreatic pseudocysts (PP) and walled-off necrosis (WON).
The majorities of WON are asymptomatic and will resolve spontaneously. Endoscopic ultrasound
(EUS)-guided drainage has become the preferred treatment in the management of symptomatic
PFC, with significant advantages compared with surgical and percutaneous drainage. Successful
endoscopic management of the pancreatic fluid collections depends on the type of PFC. Studies
have shown that endoscopic drainage of PP is greater than 90%, while success for WON is at
best between 50-65%. Differences in treatment outcome are attributed to the viscosity and
debris content of the PFC. Traditionally, the EUS-guided drainage has been performed with
placement of multiple plastic stents or fully covered self-expanding metal stent.
Recently, lumen-apposing metal stents (LAMS) have been developed. LAMS have been utilized for
the access and drainage of pancreatic fluid collections (PFCs). To date, a variety of LAMS
sizes have been commercially available and widely used. Studies have shown high technical
success (89-100%) and high clinical success rate (93-100%). The larger diameter of LAMS
facilitates better drainage of PFC contents when compared to the small caliber of plastic
stents and allows necrosectomy in repeated sessions without the need for stent replacement.
A new LAMS with a larger (20mm) lumen diameter (the Hot Axios, Boston Scientific, Natick MA,
USA) was released on the market, with the idea that a larger diameter would allow a faster
drainage of PFCs and facilitate endoscopic necrosectomy. This is currently the largest
diameter LAMS available.
Further studies are needed to determine the ideal size for a LAMS going forward to achieve
maximal clinical benefit with minimal patient risk.
Aim of the investigator's study is to evaluate the safety and efficacy of the new 20 mm Hot
Axios stent placement for EUS-guided transmural drainage of pancreatic fluid collections.
Pancreatic fluid collections (PFC) can occur as a complication of acute and chronic
pancreatitis. PFC include pancreatic pseudocysts (PP) and walled-off necrosis (WON).
The majorities of WON are asymptomatic and will resolve spontaneously. Endoscopic ultrasound
(EUS)-guided drainage has become the preferred treatment in the management of symptomatic
PFC, with significant advantages compared with surgical and percutaneous drainage. Successful
endoscopic management of the pancreatic fluid collections depends on the type of PFC. Studies
have shown that endoscopic drainage of PP is greater than 90%, while success for WON is at
best between 50-65%. Differences in treatment outcome are attributed to the viscosity and
debris content of the PFC. Traditionally, the EUS-guided drainage has been performed with
placement of multiple plastic stents or fully covered self-expanding metal stent.
Recently, lumen-apposing metal stents (LAMS) have been developed. LAMS have been utilized for
the access and drainage of pancreatic fluid collections (PFCs). To date, a variety of LAMS
sizes have been commercially available and widely used. Studies have shown high technical
success (89-100%) and high clinical success rate (93-100%). The larger diameter of LAMS
facilitates better drainage of PFC contents when compared to the small caliber of plastic
stents and allows necrosectomy in repeated sessions without the need for stent replacement.
A new LAMS with a larger (20mm) lumen diameter (the Hot Axios, Boston Scientific, Natick MA,
USA) was released on the market, with the idea that a larger diameter would allow a faster
drainage of PFCs and facilitate endoscopic necrosectomy. This is currently the largest
diameter LAMS available.
Further studies are needed to determine the ideal size for a LAMS going forward to achieve
maximal clinical benefit with minimal patient risk.
Aim of the investigator's study is to evaluate the safety and efficacy of the new 20 mm Hot
Axios stent placement for EUS-guided transmural drainage of pancreatic fluid collections.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04205058 -
Coffee After Pancreatic Surgery
|
N/A | |
Completed |
NCT02971579 -
A Register on the Quality of ERCP and Training of Endoscopists in Italy
|
||
Not yet recruiting |
NCT01900938 -
Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP
|
N/A | |
Completed |
NCT01427725 -
Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
|
||
Not yet recruiting |
NCT05954221 -
Red Cell Lysis Buffer Application Versus Conventional Sample Processing in EUS-FNB
|
N/A | |
Enrolling by invitation |
NCT02471170 -
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
|
||
Completed |
NCT04705740 -
Influence of the Endoscopists and Endoscopic Retrograde CholangioPanceratography
|
||
Recruiting |
NCT04259580 -
Calgary Registry for Advanced and Therapeutic Endoscopy
|
||
Recruiting |
NCT04291651 -
UCSF PANC Cyst Registry
|
||
Enrolling by invitation |
NCT03234543 -
Remote Ischemic Conditioning in Abdominal Surgery
|
N/A | |
Completed |
NCT02916199 -
Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method
|
N/A | |
Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
Recruiting |
NCT05249400 -
Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training
|
N/A | |
Recruiting |
NCT05824403 -
PAncreatic Disease Cohort of TOuLouse
|
||
Active, not recruiting |
NCT03269994 -
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
|
Phase 3 | |
Enrolling by invitation |
NCT04329039 -
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
|
Phase 2/Phase 3 | |
Completed |
NCT03198871 -
IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population
|
Phase 4 | |
Completed |
NCT02337673 -
Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
|
||
Completed |
NCT01964430 -
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
|
Phase 3 |